Novartis AG - ADR

Novartis AG - ADR

NVS

Market Cap$201.28B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novartis AG - ADRNovartis AG - ADR11.73.67%41%4.20.7

Earnings Call Q3 2024

October 29, 2024 - AI Summary

**Strong Financial Performance**: Novartis reported a 10% increase in net sales and a 20% rise in core operating income for Q3 2024, with core EPS also up 20% to $2.06. This consistent growth reflects robust sales across its key brands and successful innovations, which should provide a solid base as the company approaches the mid-2025 LoE for key products like Entresto, Tasigna, and Promacta.
**Pipeline and Product Launches**: Significant developments include the FDA approval of Kisqali for early breast cancer, accelerated approval of Fabhalta in IgA nephropathy, and expectations for Scemblix approval shortly. Analysts expect these new indications to potentially triple the eligible patient population, especially with Kisqali benefiting from a broader NCCN guideline recommendation.
**Revised Financial Guidance**: For the third time in 2024, Novartis raised its guidance for both top and bottom line performance, projecting low double-digit sales growth and high-teens core operating income growth, assuming no generics enter the U.S. market for Entresto or Tasigna in 2024.

Exclusive for Stockcircle Pro members

Sign upSign Up
$120.50

Target Price by Analysts

18.1% upsideNovartis AG Target Price DetailsTarget Price
$105.79

Current Fair Value

3.7% upside

Undervalued by 3.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$201.28 Billion
Enterprise Value$220.15 Billion
Dividend Yield$3.78 (3.67442378354303%)
Earnings per Share$7.15
Beta0.51
Outstanding Shares2,012,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio11.69
PEG13.73
Price to Sales4.25
Price to Book Ratio4.86
Enterprise Value to Revenue4.5
Enterprise Value to EBIT15.95
Enterprise Value to Net Income12
Total Debt to Enterprise0.15
Debt to Equity0.75

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Novartis AG

CEO: Vasant Narasimhan

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...